These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35952426)

  • 21. Phase II Trial of the Impact 0.5% Povidone-Iodine Nasal Spray (Nasodine®) on Shedding of SARS-CoV-2.
    Friedland PL; Tucker S
    Laryngoscope; 2024 Sep; 134(9):3947-3952. PubMed ID: 38554057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial.
    Castellarnau A; Heery GP; Seta A; Luscombe CA; Kinghorn GR; Button P; McCloud P; Paull JRA
    Sci Rep; 2022 Jun; 12(1):10210. PubMed ID: 35715644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cluster randomised, controlled, triple-blind trial assessing the efficacy of intranasally administered virus-neutralising bovine colostrum supplement in preventing SARS-CoV-2 infection in household contacts of SARS-CoV-2-positive individuals: a study protocol.
    Uusküla A; Keis A; Toompere K; Planken A; Rebrov K
    Trials; 2022 Jan; 23(1):92. PubMed ID: 35101094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
    Smolenov I; Han HH; Li P; Baccarini C; Verhoeven C; Rockhold F; Clemens SAC; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R;
    Lancet Infect Dis; 2022 Jul; 22(7):990-1001. PubMed ID: 35447085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
    Herman GA; O'Brien MP; Forleo-Neto E; Sarkar N; Isa F; Hou P; Chan KC; Bar KJ; Barnabas RV; Barouch DH; Cohen MS; Hurt CB; Burwen DR; Marovich MA; Musser BJ; Davis JD; Turner KC; Mahmood A; Hooper AT; Hamilton JD; Parrino J; Subramaniam D; Baum A; Kyratsous CA; DiCioccio AT; Stahl N; Braunstein N; Yancopoulos GD; Weinreich DM;
    Lancet Infect Dis; 2022 Oct; 22(10):1444-1454. PubMed ID: 35803290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
    Tanriover MD; Doğanay HL; Akova M; Güner HR; Azap A; Akhan S; Köse Ş; Erdinç FŞ; Akalın EH; Tabak ÖF; Pullukçu H; Batum Ö; Şimşek Yavuz S; Turhan Ö; Yıldırmak MT; Köksal İ; Taşova Y; Korten V; Yılmaz G; Çelen MK; Altın S; Çelik İ; Bayındır Y; Karaoğlan İ; Yılmaz A; Özkul A; Gür H; Unal S;
    Lancet; 2021 Jul; 398(10296):213-222. PubMed ID: 34246358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zhu FC; Guan XH; Li YH; Huang JY; Jiang T; Hou LH; Li JX; Yang BF; Wang L; Wang WJ; Wu SP; Wang Z; Wu XH; Xu JJ; Zhang Z; Jia SY; Wang BS; Hu Y; Liu JJ; Zhang J; Qian XA; Li Q; Pan HX; Jiang HD; Deng P; Gou JB; Wang XW; Wang XH; Chen W
    Lancet; 2020 Aug; 396(10249):479-488. PubMed ID: 32702299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.
    Liu Y; Zhang J; Liu W; Pan Y; Ruan S; Nian X; Chen W; Sun L; Yin Q; Yue X; Li Q; Gui F; Wu C; Wang S; Yang Y; Jing Z; Long F; Wang Z; Zhang Z; Huang C; Duan K; Liang M; Yang X
    Emerg Microbes Infect; 2024 Dec; 13(1):2284297. PubMed ID: 37970736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
    Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T;
    Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nasal spray of an IgM-like ACE2 fusion protein HH-120 prevents SARS-CoV-2 infection: Two investigator-initiated postexposure prophylaxis trials.
    Song R; Chen X; Li B; Ni J; Zhou Y; Zhang H; Liang X; Zou L; Liu J; Yang F; Li G; Guo X; Liu Z; Mao F; Lei C; Sui J; Li W; Jin R
    J Med Virol; 2023 Dec; 95(12):e29275. PubMed ID: 38054556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial.
    Tandon M; Wu W; Moore K; Winchester S; Tu YP; Miller C; Kodgule R; Pendse A; Rangwala S; Joshi S;
    Lancet Reg Health Southeast Asia; 2022 Aug; 3():100036. PubMed ID: 35784831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
    Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
    Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial.
    Robbins JA; Tait D; Huang Q; Dubey S; Crumley T; Cote J; Luk J; Sachs JR; Rutkowski K; Park H; Schwab R; Howitt WJ; Rondon JC; Hernandez-Illas M; O'Reilly T; Smith W; Simon J; Hardalo C; Zhao X; Wnek R; Cope A; Lai E; Annunziato P; Guris D; Stoch SA
    EBioMedicine; 2022 Aug; 82():104138. PubMed ID: 35809371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salivary and Nasal Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses (BBCovid): A structured summary of a study protocol for a randomised controlled trial.
    Carrouel F; Viennot S; Valette M; Cohen JM; Dussart C; Bourgeois D
    Trials; 2020 Nov; 21(1):906. PubMed ID: 33138848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nasal spray of an IgM-like ACE2 fusion protein HH-120 accelerates SARS-CoV-2 clearance: A single-center propensity score-matched cohort study.
    Song R; Chen X; Li B; Zhang H; Guo X; Liu Z; Zou L; Liang X; Lei C; Mao F; Sui J; Li W; Jin R
    J Med Virol; 2023 May; 95(5):e28805. PubMed ID: 37227062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study).
    Namiki T; Takayama S; Arita R; Ishii T; Kainuma M; Makino T; Mimura M; Yoshino T; Nogami T; Arai M; Sato J; Tanaka K; Nakae H; Igari H; Ozawa Y; Shiko Y; Kawasaki Y; Nezu M; Ito T
    Trials; 2021 Jan; 22(1):23. PubMed ID: 33407828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.